The majority of the $6 trillion spent annually on health care globally is focused on the treatment of patients that have diseases with either a cellular damage or degeneration component.
Unfortunately, the current therapeutic tools used to address these needs, including organ transplantation, traditional pharmaceuticals, and, more recently, stem cell therapies, fall very short of actual cures.
Corporate Presentation 2013
Organ transplantation is limited by a substantial and growing donor gap and the unavoidable host-versus-graft reaction. Traditional pharmaceuticals, while capable of interfering and slowing down degenerative processes, can do little to reverse damage once it has occurred, and typically only target the late-appearing indications of dysfunctional tissue / organ systems, as opposed to the biological factors that cause these abnormalities. Even the evolving stem cell space is running into many technical, efficacy, and regulatory challenges which will substantially limit the potential of the market for these replacement therapies.
An alternative, cost-efficient approach is required that can simultaneously address regeneration and repair therapeutic indications, leverage existing pharmaceutical regulatory pathways, and avoid the many limitations of the healthcare industry’s current offerings.
Combinatorial biologics that are capable of directly modifying biological regulatory state, such as Bioquark’s lead candidate, BQ-A, fulfill all of these criteria.